WHAT IS CLAIMED IS:

~~1. A method of treating vitiligo in a patient comprising topically administering to an affected skin area of the patient in need thereof a pharmaceutical composition containing about 1.5% w/w ruxolitinib, or a pharmaceutically acceptable salt thereof, on a free base basis, twice per day.~~

~~2. The method of claim 1, wherein the vitiligo is generalized vitiligo.~~

~~3. A method of treating vitiligo in a patient comprising topically administering to an affected skin area of the patient in need thereof a pharmaceutical composition containing about 1.5% w/w ruxolitinib, or a pharmaceutically acceptable salt thereof, on a free base basis, twice per day, wherein the affected area is selected from lower extremities, trunk, hands, upper extremities, and feet.~~

~~4. The method of claim 3, wherein the affected skin area is the lower extremities of the patient.~~

~~5. The method of claim 3, wherein the affected skin area is the trunk of the patient.~~

~~6. The method of claim 3, wherein the affected skin area is the hands of the patient.~~

~~7. The method of claim 3, wherein the affected skin area is the upper extremities of the patient.~~

~~8. The method of claim 3, wherein the affected skin area is the feet of the patient.~~

~~9. The method of any one of claims 3-8, wherein the patient achieves a 25% or greater improvement in Vitiligo Area Scoring Index on the affected skin area.~~

~~10. The method of any one of claims 3-9, wherein the patient achieves a 50% or greater improvement in Vitiligo Area Scoring Index on the affected skin area.~~

~~11. The method of any one of claims 3-10, wherein the patient achieves a 75% or greater improvement in Vitiligo Area Scoring Index on the affected skin area.~~

~~12. The method of any one of claims 3-11, wherein the patient achieves a 50% or greater improvement in Vitiligo Area Scoring Index score on the hands of the patient at Week 4, Week 8, Week 18, Week 24, Week 32, Week 38, Week 42, Week 48, or Week 52.~~

~~13. The method of any one of claims 3-12, wherein the patient achieves a 50% or greater improvement in Vitiligo Area Scoring Index score on the upper extremities of the patient at Week 4, Week 8, Week 18, Week 24, Week 32, Week 38, Week 42, Week 48, or Week 52.~~

~~14. The method of any one of claims 3-13, wherein the patient achieves a 50% or greater improvement in Vitiligo Area Scoring Index score on the feet of the patient at Week 4, Week 8, Week 18, Week 24, Week 32, Week 38, Week 42, Week 48, or Week 52.~~

~~15. The method of any one of claims 3-14, wherein the patient achieves a 50% or greater improvement in Vitiligo Area Scoring Index score on the lower extremities of the patient at Week 4, Week 8, Week 18, Week 24, Week 32, Week 38, Week 42, Week 48, or Week 52.~~

~~16. The method of any one of claims 3-15, wherein the patient achieves a 50% or greater improvement in Vitiligo Area Scoring Index score on the trunk of the patient at Week 4, Week 8, Week 18, Week 24, Week 32, Week 38, Week 42, Week 48, or Week 52.~~

~~17. The method of claim 3, wherein:~~

~~the affected area is selected from lower extremities, trunk, hands, upper extremities, and feet;~~

~~the patient suffers from generalized vitiligo with depigmented area of: (i) 0.5% or greater body surface area (BSA) on the face, (ii) 3% or greater BSA on non-facial areas, and (iii) not exceeding 10% BSA on total body area;~~

~~the method does not comprise administering laser or any kind of phototherapy; and~~

~~the patient achieves a 50% or greater improvement in Vitiligo Area Scoring Index score on the affected skin area.~~

~~18. The method of claim 3, wherein:~~

~~the affected area is selected from lower extremities, trunk, and feet;~~

~~the patient suffers from generalized vitiligo with depigmented area of: (i) 0.5% or greater body surface area (BSA) on the face, (ii) 3% or greater BSA on non-facial areas, and (iii) not exceeding 10% BSA on total body area;~~

~~the method does not comprise administering laser or any kind of phototherapy; and~~

~~the patient achieves a 50% or greater improvement in Vitiligo Area Scoring Index score on the affected skin area.~~

~~19. A method of treating generalized vitiligo in a patient comprising topically administering to an affected skin area of the patient in need thereof a pharmaceutical composition containing about 1.5% w/w ruxolitinib, or a pharmaceutically acceptable salt~~

~~thereof, on a free base basis, twice per day, wherein the patient has a vitiligo disease duration of at least 20 years and wherein the patient achieves a 50% or greater improvement in Face Vitiligo Scoring Index.~~

~~20. The method of claim 19, wherein the affected area is face.~~

~~21. The method of claim 19, wherein the affected area is head and neck~~

~~22. The method of claim 19, wherein the affected area is selected from lower extremities, trunk, hands, upper extremities, and feet.~~

~~23. A method of treating vitiligo in a patient, comprising topically administering to an affected skin area of the patient in need thereof a pharmaceutical composition containing about 1.5% w/w ruxolitinib, or a pharmaceutically acceptable salt thereof, on a free base basis, twice per day, wherein the patient does not receive phototherapy for vitiligo during the administration of the pharmaceutical composition.~~

~~24. The method of any one of claims 1-23, wherein the patient achieves a 25% or greater improvement in Face Vitiligo Area Scoring Index.~~

~~25. The method of any one of claims 1-24, wherein the patient achieves a 50% or greater improvement in Face Vitiligo Area Scoring Index.~~

~~26. The method of any one of claims 1-25, wherein the patient achieves a 75% or greater improvement in Face Vitiligo Area Scoring Index.~~

~~27. The method of any one of claims 1-26, wherein the patient achieves a 90% or greater improvement in Face Vitiligo Area Scoring Index.~~

~~28. The method of any one of claims 1-27, wherein the patient achieves a 25% or greater improvement in Total Body Vitiligo Area Scoring Index.~~

~~29. The method of any one of claims 1-28, wherein the patient achieves a 50% or greater improvement in Total Body Vitiligo Area Scoring Index.~~

~~30. The method of any one of claims 1-29, wherein the patient achieves a 75% or greater improvement in Total Body Vitiligo Area Scoring Index.~~

~~31. The method of any one of claims 1-30, wherein the administering is for up to 24 weeks.~~

~~32. The method of any one of claims 1-31, wherein the administering is for up to 52 weeks.~~

~~33. The method of any one of claims 1-32, wherein the patient has at least 1.5% facial body surface area affected by vitiligo (F-BSA).~~

~~34. The method of any one of claims 1-33, wherein the patient has at least 1.5% facial body surface area affected by vitiligo (F-BSA) and achieves a 50% or greater improvement in Face Vitiligo Area Scoring Index score at Week 24.~~

~~35. The method of any one of claims 1-34, wherein the patient has 1.5% facial body surface area affected by vitiligo (F-BSA) and achieves a 50% or greater improvement in Face Vitiligo Area Scoring Index score at Week 52.~~

~~36. The method of any one of claims 1-35, wherein the patient has 1.5% facial body surface area affected by vitiligo (F-BSA) and achieves a 75% or greater improvement in Face Vitiligo Area Scoring Index score at Week 24.~~

~~37. The method of any one of claims 1-36, wherein the patient has at least 1.5% facial body surface area affected by vitiligo (F-BSA) and achieves a 75% or greater improvement in Face Vitiligo Area Scoring Index score at Week 52.~~

~~38. The method of any one of claims 1-37, wherein the patient achieves a 25% or greater improvement in Total Body Vitiligo Area Scoring Index score at Week 24.~~

~~39. The method of any one of claims 1-38, wherein the patient achieves a 25% or greater improvement in Total Body Vitiligo Area Scoring Index score at Week 52.~~

~~40. The method of any one of claims 1-39, wherein the patient achieves a 50% or greater improvement in Total Body Vitiligo Area Scoring Index score at Week 24.~~

~~41. The method of any one of claims 1-40, wherein the patient achieves a 50% or greater improvement in Total Body Vitiligo Area Scoring Index score at Week 52.~~

~~42. The method of any one of claims 1-41, wherein the patient achieves a 75% or greater improvement in Total Body Vitiligo Area Scoring Index score at Week 24.~~

~~43. The method of any one of claims 1-42, wherein the patient achieves a 75% or greater improvement in Total Body Vitiligo Area Scoring Index score at Week 52.~~

~~44. The method of any one of claims 1-43, wherein the patients has no greater than 10% total body surface area affected by vitiligo (T-BSA).~~

~~45. The method of any one of claims 1-44, wherein the patient has been clinically diagnosed with vitiligo.~~

~~46. The method of any one of claims 1-45, wherein the patient is aged 12 years old and older.~~

~~47. The method of any one of claims 1-45, wherein the patient is aged 18 years old and older.~~

~~48. The method of any one of claims 1-45, wherein the patient is 18 years old to 75 years old.~~

~~49. The method of any one of claims 1-45, wherein the patient is aged 50 years old or less.~~

~~50. The method of any one of claims 1-49, wherein the patient has progressive vitiligo at baseline.~~

~~51. The method of any one of claims 1-50, wherein the patient has at least 0.5% facial body surface area affected by vitiligo.~~

~~52. The method of any one of claims 1-51, wherein the patient has at least 3% non-facial body surface area affected by vitiligo.~~

~~53. The method of any one of claims 1-52, wherein the patient has no greater than 10% total body surface area affected by vitiligo.~~

~~54. The method of any one of claims 1-53, wherein the patient has a disease duration at baseline of at least 10 years.~~

~~55. The method of any one of claims 1-54, wherein the patient does not administer any other agents for the treatment of vitiligo.~~

~~56. The method of any one of claims 1-55, wherein the patient previously received phototherapy.~~

~~57. The method of any one of claims 1-56, wherein the method does not comprise administering laser or any kind of phototherapy.~~

~~58. The method of any one of claims 1-57, wherein a hemoglobin level of the patient at Week 52 is similar to a hemoglobin level of the patient at baseline.~~

~~59. The method of any one of claims 1-58, wherein a platelet level of the patient at Week 52 is similar to a platelet level of the patient at baseline.~~

~~60. The method of any one of claims 1-59, wherein there is no substantial difference in response between patients having baseline total body surface area affected by vitiligo equal to or less than 20% and patients having baseline total body surface area affected by vitiligo greater than 20%.~~

~~61. The method of any one of claims 1-60, wherein the ruxolitinib, or the pharmaceutically acceptable salt thereof, is ruxolitinib phosphate.~~

~~62. The method of any one of claims 1-61, wherein the pharmaceutical composition is a cream.~~

~~63. The method of claim 62, wherein the cream is an oil-in-water emulsion.~~

~~64. The method of claim 63, wherein the cream contains 1.5% w/w ruxolitinib phosphate on a free base basis.~~

~~65. The method of claim 64, wherein the cream has a pH of about 2.8 to about 3.9.~~

~~66. The method of claim 1, wherein the vitiligo is segmental vitiligo.~~

~~67. A pharmaceutical composition for use in any of the methods of claims 1-66.~~

~~68. Use of a pharmaceutical composition for preparation of medicament for use in any of the methods of claims 1-66.~~

1. Use of 1.5% w/w ruxolitinib, or a pharmaceutically acceptable salt thereof, on a free base basis, in the manufacture of a pharmaceutical composition for the treatment of vitiligo in an affected area of a patient,

wherein the pharmaceutical composition is to be topically administered to the affected skin area of the patient twice per day, and the vitiligo is nonsegmental vitiligo,

wherein the affected skin area comprises at least one of lower extremities, trunk, and feet of the patient, and

wherein the treatment does not comprise phototherapy.

2. The use of claim 1, wherein the ruxolitinib, or the pharmaceutically acceptable salt thereof, is ruxolitinib phosphate.

3. The use of claim 1, wherein the affected skin area comprises the lower extremities of the patient.

4. The use of claim 1, wherein the affected skin area comprises the trunk of the patient.

5. The use of claim 1, wherein the affected skin area comprises the feet of the patient.

6. The use of claim 1, wherein the pharmaceutical composition is to be topically administered and is to be continued until the patient achieves an increase in pigmentation in the affected skin area that is at least one of the lower extremities, the trunk, and the feet.

7. The use of claim 6, wherein the pharmaceutical composition is to be topically administered for at least 52 weeks.

8. The use of claim 1, wherein the pharmaceutical composition is to be topically administered and is to be continued until the patient achieves an increase in pigmentation in the affected skin area that is the lower extremities.

9. The use of claim 1, wherein the pharmaceutical composition is to be topically administered and is to be continued until the patient achieves an increase in pigmentation in the affected skin area that is the trunk.

10. The use of claim 1, wherein the pharmaceutical composition is to be topically administered and is to be continued until the patient achieves an increase in pigmentation in the affected skin area that is the feet.

11. The use of claim 6, wherein the patient achieves a 25% or greater improvement in Vitiligo Area Scoring Index in the affected skin area that is at least one of the lower extremities, the trunk, and the feet after 52 weeks of the administering.

12. The use of claim 6, wherein the patient:

has at least 0.5% facial body surface area affected by vitiligo at baseline and at least 3% non-facial body surface area affected by vitiligo at baseline; and

has been clinically diagnosed with vitiligo.

13. The use of claim 12, wherein the patient is aged 12 years or older.

14. The use of claim 1, wherein the pharmaceutical composition is an oil-in-water emulsion, which is a cream.

15. Use of 1.5% w/w ruxolitinib, or a pharmaceutically acceptable salt thereof, on a free base basis, in the manufacture of a pharmaceutical composition for the treatment of vitiligo in an affected area of a patient,

wherein the pharmaceutical composition is to be topically administered to the affected skin area of the patient twice per day, and the vitiligo is nonsegmental vitiligo,

wherein the affected skin area comprises at least one of lower extremities, trunk, and feet of the patient,

wherein the treatment does not comprise phototherapy, and

wherein the pharmaceutical composition is to be topically administered and is to be continued to achieve a 50% or greater improvement in Vitiligo Area Scoring Index in the affected skin area that is at least one of the lower extremities, the trunk, and the feet after 52 weeks.

16. The use of claim 15, wherein the patient:

has at least 0.5% facial body surface area affected by vitiligo at baseline and at least 3% non-facial body surface area affected by vitiligo at baseline; and

has been clinically diagnosed with vitiligo.

17. The use of claim 16, wherein the patient is aged 12 years or older.

18. The use of claim 15, wherein the pharmaceutical composition is an oil-in-water emulsion, which is a cream.

19. The use of claim 15, wherein the affected skin area is the lower extremities.

20. The use of claim 15, wherein the affected skin area is the trunk.

21. The use of claim 15, wherein the affected skin area is the feet.